Diabetic nephropathy: Prevention and early referral

Canadian Family Physician

Volumn 46, Issue MAR., 2000, Pages 636-642

  Pylypchuk, G ^a   Beaubien, E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

DIABETIC NEPHROPATHY; DISEASE COURSE; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN RESTRICTION; REVIEW; SMOKING CESSATION; TREATMENT INDICATION;

CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FAMILY PRACTICE; HUMANS; PREVENTIVE MEDICINE; REFERRAL AND CONSULTATION;

EID: 0034094662     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998;338(20):1428-37.
2. Schaubel DE, Marrison HI, Desmeules M, Parsons DA, Fenton SSA. End-stage renal disease in Canada: prevalence projections to 2005. Can Med Assoc J 1999;160(11):1557-63.
3. Canadian Institute for Health Information. Canadian organ replacement register. Ottawa, Ont Canadian Institute for Health Information; 1997.
4. United States Renal Disease Report USRDS. Annual Report. Am J Kidney Dis 1998;32(2 Suppl 1)):S38-49.
5. Dyck RF, Tan L. Rates and outcomes of diabetic end-stage renal disease among registered native people in Saskatchewan. Can Med Assoc J 1994;150(2):203-8.
6. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(Suppl 5):S1-S85.
7. Defronz R. Diabetic nephropathy etiologies and therapeutic considerations. Diabetes Rev 1995;3(3):510-47.
8. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996;27(2):167-94.
9. Suzuki Y, Ueno M, Hayashi H, Nishi S, Satou H, Karasawa R, et al. A light microscopic study of glomerulosclerosis in Japanese patients with noninsulin-dependent diabetes mellitus: the relationship between clinical and histological features. Clin Nephrol 1994;42(3):155-62.
10. Keane WF, Anderson S, Aurell M, de Zeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions. Ann Intern Med 1989;111(6):503-16.
11. Mogenson CE. Prevention and treatment of renal disease in insulin-dependent diabetes mellitus. Semin Nephrol 1990;10:260-73.
12. Jacobson E. Diabetic nephropathy. Dialysis Transplant 1994;23(11):616-24.
13. Mogenson CE. Natural history of renal functioning abnormalitis in human diabetes mellitis: from microalbuminuria to incipient and overt nephropathy. Semin Nephrol 1989;20:19-49.
14. Knowlewski A, Wanan J. Natural history of diabetic nephropathy. Diabetes Rev 1995;3(3):446-58.
15. Hindmarsh JT. Microalbuminuria. Clin Lab Med 1988;8(3):611-6.
16. Ruilope L, Rodicio J. Microalbuminurea in clinical practice. In: Kidney: a current survey of world literature. New York, NY: Springer-Verlag; 1995. p. 211-6.
17. Mogenson CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346(8982):10804.
18. Melchior WR, Bindlish V, Jaber LA. Angiotensin-converting enzyme inhibitors in diabetic nephropathy. Ann Pharmacother 1993;27(3):344-50.
19. Brenner and Rector. The kidney. 5th ed. Toronto, Ont WB Saunders; 1996.
20. Mogensen CE. Microalbuminuria predicts clinical proteinurea and early mortality in maturity-onset diabetes. N Engl J Med 1984;310(6):356-60.
21. Jarrett RJ, Viberti GC, Argyropoulos A, Hill RD, Mahmud U, Murrells TJ. Microalbuminuria predicts mortality in non insulin-dependent diabetics. Diabet Med 1984;1(1):17-9.
22. Holley JL. Nephrologists as primary care providers: a review of the issues. Am J Kidney Dis 1998;31(4):574-83.
23. Martinez-Maldonado M, Sattin RW. Rate of progression of renal disease and low-protein diet. Am J Kidney Dis 1998;31(6):1048-9.
24. Kasike BL, Lakuta JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998;31(6):954-61.
25. UK Prospective Diabetes Study (UKPDS). Intensive blood glucose control with sulfonylureas or insulin compared with conventional therapy and risk of complications of patients with type 2 diabetes. Lancet 1998;352:837-53.
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329(14):977-86.
27. Molitch ME. Management of early diabetic nephropathy. Am J Med 1997;102(4):392-8.
28. HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351(9118):1755-62.
29. Stein PP, Black HR. Drug treatment of hypertension of patients with diabetes mellitus. Diabetes Care 1991;14(6):425-48.
30. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997;29(2):641-50.
31. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
32. Guidelines Subcommittee. 1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-83.
33. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, Floras JS, et al. 1999 Canadian recommendations for the management of hypertension. Can Med Assoc J 1999;161(Suppl 12):1-22.
34. The EUCLID Study Group. Randomized placebo-controlled trial of lisinopril in nor-motensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349(9068):1787-92.
35. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20(10):1576-81.
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotension-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1997;329(20):1456-62.
37. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE, et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991;265(5):614-7.
38. Gambaro G, Verlato F, Budakovic A, Casara D, Saladini G, Del Prete D, et al. Renal impairment in chronic cigarette smokers. J Am Soc Nephrol 1997;9(4):562-7.
39. Ravid M, Brosh D, Ravid-Safron D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med 1998;158:998-1004.
40. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38(5):604-9.
41. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995;25(1):107-12.
42. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yale ZF, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998;159(Suppl 8):S1-S29.